Pen Injectors Becoming Commonplace in Self-Administration for Key Chronic Indications

(openPR) (Amherst, NH) – The evolution in drug injection devices to accommodate new injectable drugs designed for self-administration continues to change the therapeutic drug landscape. Attempting to address key healthcare issues that include patient safety and drug protocol compliance, device designers are now building on the experience of earlier generations of syringes and injectors, incorporating new design features with the aim of making the injection event more consistent across patient populations and less likely to evoke feelings of apprehension.

In this environment, pen injectors have found strong user acceptance for a number of chronic conditions, a list that includes autoimmunity, diabetes, osteoporosis and reproductive medicine. On a global basis, the growth of pen injectors in these therapeutic segments continues to climb, already representing the majority of injections in several, including hormone replacement and selected metabolic diseases (diabetes, osteoporosis).

While pen injectors represent a significant cost premium over syringes, drug companies are finding that customized pen devices can be important product differentiators in direct-to-consumer markets. This awareness has created opportunities for specialty pen device suppliers such as Ypsomed, which continues to dominate in this market. As pen devices become more entrenched in the strategies of injectable drug developers, alternative device acquisition strategies will put pressure on the traditional outsourcing models.

Detailed analysis of pen injector products, therapeutic sectors, and participants is included in a new and comprehensive report. The report documents and analyzes the results of a recent survey of pen injector drug delivery conducted by Greystone Research Associates.

More information is available at
http://www.greystoneassociates.org/Pen_Injectors.htm



Source: Greystone Research Associates